Full video transcriptClick to expand
Auto-generated transcript of @my.journey.with.marc's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00Whoa, so this injection site just hit different and if you are in a DLP like
- 0:04Majora or a GoV like me and your job fails to only randomly work, this is for you.
- 0:08So I've tried everywhere but what happened today genuinely shocked me and I
- 0:13haven't said that a lot on my journey but I will tell you exactly what to do so I
- 0:16lost 126 pounds in just under a year on Majora and I did share everything I wish
- 0:20someone told me when I started this back in 2024 and if you're worried about
- 0:23your skin on this journey like I am drop the word skin in the comments and I mess
- 0:26with you with what has helped me because we're storing elasticity and firmness and
- 0:29that buttons back into your skin needs a targeted approach and most skincare
- 0:32isn't built for our journey. If you are figuring this journey out as you go with
- 0:35this page my journey with Mark will hopefully help you a lot of the trial and
- 0:37error. So yesterday I used the top of my thigh gain. As always and I'm not
- 0:41exaggerating the suppression today isn't seeing completely in seeing and on my
- 0:45experience I have tried the stomach, underarm, I've moved through all the
- 0:48recommended spots but the top of my thigh it just always feels more consistent
- 0:52way stronger and way more controlled throughout the day. Now just to be clear I
- 0:56only respect to the approved injection sites and this is just what I personally
- 1:00noticed but what I didn't realize at the start of this is that where you inject
- 1:04can actually change how it feels and works for you. So I didn't figure this
- 1:07out until months in and when I did genuinely changed things for me. So this
- 1:11week I went back to B6 protein protein protein and my suppression is through
- 1:14the roof this crazy. So there's a lot can be said for taking this and staying on
- 1:17track for results. So let me know, be honest, have you found once a while that works
- 1:22better for you than others let me know what it is in the comments to help
- 1:25other people out or are you still testing or have you another question drop
- 1:28up a little or if you want to get your elasticity back into your skin and
- 1:30comment skin and I'll come back to you. I'll catch you in the next one.
Does your GLP-1 injection site actually change how well it works?
Quick answer
Tirzepatide (Mounjaro) and semaglutide (Wegovy) are approved for subcutaneous injection into the abdomen, upper thigh, or upper arm, with prescribing information for both indicating these sites are interchangeable in terms of pharmacokinetic outcomes. Individual variation in subcutaneous fat depth, tissue perfusion, and lipohypertrophy from repeated injection can plausibly affect local absorption, but no peer-reviewed evidence specifically demonstrates that the thigh produces superior appetite suppression in GLP-1 users. Any perceived change in drug effect following both a site switch and a dietary change cannot be reliably attributed to either variable alone.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Semaglutide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 9 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Does your GLP-1 injection site actually change how well it works?, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
Compounded Semaglutide should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.
Claim path
Keep researching this semaglutide video claims cluster
Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "Does your GLP-1 injection site actually change how well it works?" from My Journey with Marc. We read the clip as a GLP-1 social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Tirzepatide (Mounjaro) and semaglutide (Wegovy) are approved for subcutaneous injection into the abdomen, upper thigh, or upper arm, with prescribing information for both indicating these sites are interchangeable in terms of pharmacokinetic outcomes.
The reason this review is not generic is the source wording and the canonical claim label "glp1 didn t expect this at all switching injection sites made a n." In this clip, the useful excerpt is: "Whoa, so this injection site just hit different and if you are in a DLP like Majora or a GoV like me and your job fails to only randomly work, this is for you." That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.
The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
Tirzepatide (Mounjaro) and semaglutide (Wegovy) are approved for subcutaneous injection into the abdomen, upper thigh, or upper arm, with prescribing information for both indicating these sites are interchangeable in terms of pharmacokinetic outcomes.
FormBlends verdict
Compounded Semaglutide safety, access, evidence, and fit
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Tirzepatide (Mounjaro) and semaglutide (Wegovy) are approved for subcutaneous injection into the abdomen, upper thigh, or upper arm, with prescribing information for both indicating these sites are interchangeable in terms of pharmacokinetic outcomes. Individual variation in subcutaneous fat depth, tissue perfusion, and lipohypertrophy from repeated injection can plausibly affect local absorption, but no peer-reviewed evidence specifically demonstrates that the thigh produces superior appetite suppression in GLP-1 users. Any perceived change in drug effect following both a site switch and a dietary change cannot be reliably attributed to either variable alone.
- Tirzepatide and semaglutide prescribing information list the abdomen, upper thigh, and upper arm as clinically interchangeable injection sites with no pharmacokinetic superiority assigned to any one location.
- Lipohypertrophy from injecting the same spot repeatedly is a documented cause of reduced drug absorption. Rotating sites within and between approved locations is standard clinical guidance (Frid et al., 2016, Mayo Clinic Proceedings).
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.
Review Compounded SemaglutideWhat You'll Learn
- Tirzepatide and semaglutide prescribing information list the abdomen, upper thigh, and upper arm as clinically interchangeable injection sites with no pharmacokinetic superiority assigned to any one location.
- Lipohypertrophy from injecting the same spot repeatedly is a documented cause of reduced drug absorption. Rotating sites within and between approved locations is standard clinical guidance (Frid et al., 2016, Mayo Clinic Proceedings).
- The creator changed both their injection site and increased protein intake in the same week, making it impossible to determine which change, if either, drove the reported improvement in suppression.
- High protein diets independently increase satiety independent of GLP-1 medication. Leidy et al. (2015, American Journal of Clinical Nutrition) found higher protein intake reduced appetite-related hormones in controlled conditions.
- The SURMOUNT-1 trial found tirzepatide produced up to 22.5% body weight loss over 72 weeks. Weight loss outcomes depend on dose, adherence, and overall dietary pattern, not injection site selection.
- Subcutaneous fat depth and tissue composition vary significantly between individuals and body sites. Someone who consistently injects into muscle rather than fat at one site would likely see real differences when switching, which is a technique issue, not a site superiority issue.
- If your GLP-1 medication feels inconsistent, injection technique and site rotation are legitimate things to review with your prescriber. A TikTok anecdote is a reasonable prompt for that conversation, not a substitute for it.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @my.journey.with.marc actually say?
The creator claims that switching to the thigh as an injection site for Mounjaro produced noticeably stronger and more consistent appetite suppression than the stomach or underarm. They said the thigh "always feels more consistent, way stronger and way more controlled throughout the day." They also linked increased protein intake this week to their suppression feeling "through the roof," mixing two variables in the same breath without separating them.
To their credit, they were careful to say they "only respect the approved injection sites" and repeatedly framed the observation as personal experience. They did not tell viewers to abandon other sites or claim a medical mechanism. The video is essentially an n=1 anecdote attached to 348,000 viewers, which is where the public health stakes come in.
Does the science back this up?
Partially, and more than you might expect. Injection site does affect pharmacokinetics, though the evidence is nuanced and tirzepatide-specific data is thin.
The general principle is real. A 2021 review by Heise et al. in Diabetes, Obesity and Metabolism confirmed that subcutaneous absorption rates for insulin and other injectables vary by site, with the abdomen typically showing faster absorption than the thigh. For GLP-1 receptor agonists specifically, the picture is less clear. Semaglutide (Wegovy, Ozempic) trials used abdomen, thigh, and upper arm interchangeably with no significant difference in pharmacokinetic outcomes reported in the SUSTAIN trial program (Marso et al., 2016, NEJM). Tirzepatide's prescribing information for Mounjaro similarly lists abdomen, thigh, and upper arm as equivalent sites.
However, "statistically equivalent" in a clinical trial does not mean identical in every individual body. Subcutaneous fat depth, vascularity, and tissue perfusion differ person to person and site to site. A person who consistently hits muscle in the abdomen but gets clean subcutaneous tissue in the thigh would see a real difference. The creator's observation is plausible, even if unverifiable.
What did they get wrong (or right)?
The protein claim is where things get sloppy. They say "this week I went back to B6 protein protein protein and my suppression is through the roof" in the same video where they are crediting the thigh injection. That is two confounded variables presented as one conclusion. High protein intake does independently support satiety, there is solid evidence for that (Leidy et al., 2015, American Journal of Clinical Nutrition), but you cannot isolate the injection site effect when you also changed your diet in the same week. The creator does not acknowledge this, which is a real problem when the video's premise is specifically about injection site impact.
What they got right: the acknowledgment that everyone's experience differs, the reminder to stick to approved sites, and the general observation that site consistency matters. Rotating sites to avoid lipohypertrophy, which can genuinely impair drug absorption, is standard clinical guidance (Frid et al., 2016, Mayo Clinic Proceedings).
What should you actually know?
The approved injection sites for both tirzepatide and semaglutide are the abdomen, upper thigh, and upper arm. The clinical trials for both drugs did not find meaningful pharmacokinetic differences between these sites in general populations. That said, individual variation is real, and lipohypertrophy from repeatedly injecting the same spot can reduce absorption, which is well-documented.
If you feel like your medication is working inconsistently, injection technique is a reasonable thing to examine with your prescriber. Are you hitting subcutaneous tissue or muscle? Are you rotating within a site, not just between sites? Is the area affected by scar tissue? These are legitimate clinical questions.
What you should not do is conclude from one person's TikTok that the thigh is categorically superior. The creator lost 126 pounds in under a year, which is a significant result, but that outcome is driven by the drug's mechanism, caloric patterns, and adherence, not a single injection site switch. Treat this as a prompt to talk to your care team, not a protocol to copy.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
My Journey with Marc · TikTok creator
348.7K views on this video
Didn’t expect this at all… switching injection sites made a noticeable difference for me on my #mounjaro journey. This one was the best injection site for me and can be for you too on mounjaro or #Wegovy Everyone’s experience is different, but this is something I wish I tried at the start. Save this for later and let me know what’s worked for you. #FYP
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about tirzepatide?
Tirzepatide and semaglutide prescribing information list the abdomen, upper thigh, and upper arm as clinically interchangeable injection sites with no pharmacokinetic superiority assigned to any one location.
What does the video say about lipohypertrophy from injecting the same spot repeatedly?
Lipohypertrophy from injecting the same spot repeatedly is a documented cause of reduced drug absorption. Rotating sites within and between approved locations is standard clinical guidance (Frid et al., 2016, Mayo Clinic Proceedings).
What does the video say about the creator changed both their injection site?
The creator changed both their injection site and increased protein intake in the same week, making it impossible to determine which change, if either, drove the reported improvement in suppression.
What does the video say about high protein diets independently increase satiety independent of glp-1 medication.?
High protein diets independently increase satiety independent of GLP-1 medication. Leidy et al. (2015, American Journal of Clinical Nutrition) found higher protein intake reduced appetite-related hormones in controlled conditions.
What does the video say about the surmount-1 trial found tirzepatide produced up to 22.5% body?
The SURMOUNT-1 trial found tirzepatide produced up to 22.5% body weight loss over 72 weeks. Weight loss outcomes depend on dose, adherence, and overall dietary pattern, not injection site selection.
What does the video say about subcutaneous fat depth?
Subcutaneous fat depth and tissue composition vary significantly between individuals and body sites. Someone who consistently injects into muscle rather than fat at one site would likely see real differences when switching, which is a technique issue, not a site superiority issue.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by My Journey with Marc, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.